Eli Lilly and Co (MEX:LLY) Securities & Investments


MEX:LLY Eli Lilly and Co MEX:LLY
97 GF Score
Price MXN19,495.00
GF Value MXN24,745.36
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Eli Lilly and Co Securities & Investments?

Securities & Investments only applies to banks.

MEX:LLY
97GF Score
Eli Lilly and Co MEX:LLY
Securities & Investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Eli Lilly and Co (MEX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of MXN19,495.00 is trading 21.2% below its estimated GF Value™ of MXN24,745.36. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for MEX:LLY:

  • Securities & Investments:
  • GF Value™: MXN24,745.36 vs. price of MXN19,495.00 (21.2% below fair value)
  • GF Score™: 97/100 with 5 warning signs

No single metric tells the full story. See the MEX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
97GF Score

Get the complete analysis for MEX:LLY

Securities & Investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN19,495.00
Price
MXN24,745.36
GF Value